This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Medtronic (MDT) to Expand Diabetes Care With New Buyout
by Zacks Equity Research
Medtronic's (MDT) latest acquisition will increase its capacity to assist more individuals with diabetes worldwide within a single, seamless Medtronic support ecosystem.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
Medtronic (MDT) Q4 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Strong growth in the Cardiovascular, Medical Surgical, and Neuroscience portfolios, and in Diabetes markets drove Medtronic (MDT) Q4 revenues.
Compared to Estimates, Medtronic (MDT) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Medtronic (MDT) give insight into how the company performed in the quarter ended April 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Medtronic (MDT) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Medtronic (MDT) delivered earnings and revenue surprises of 0.64% and 3.59%, respectively, for the quarter ended April 2023. Do the numbers hold clues to what lies ahead for the stock?
Medtronic's (MDT) EV ICD Pivotal Study Shows Favorable Outcome
by Zacks Equity Research
Medtronic (MDT) announces that the findings of the EV ICD Pivotal Study reinforce device safety and effectiveness.
What's in the Cards for Medtronic (MDT) in Q4 Earnings?
by Zacks Equity Research
Medtronic (MDT) is likely to have prioritized its R&D investments, which might get reflected in the fiscal Q4 results.
Medtronic's (MDT) Global Market Share Strong, FX Headwind Stays
by Zacks Equity Research
Within cardiac rhythm management, Medtronic's (MDT) pacing business continues to outperform the market, banking on strong global growth of its Micra leadless pacemaker family.
Medtronic (MDT) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Medtronic (MDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medtronic (MDT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Medtronic (MDT) closed at $89.31, marking a +0.48% move from the previous day.
Haemonetics (HAE) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Haemonetics (HAE) delivered earnings and revenue surprises of 13.24% and 6.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Zevia (ZVIA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Zevia (ZVIA) delivered earnings and revenue surprises of 76.47% and 3.59%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Medtronic (MDT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Medtronic (MDT) closed the most recent trading day at $90.19, moving +0.14% from the previous trading session.
Medtronic (MDT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Medtronic (MDT) closed the most recent trading day at $90.68, moving -0.3% from the previous trading session.
Medical Device Stocks' Q1 Earnings on Apr 27: WST, DXCM, BAX
by Zacks Equity Research
Medical Device companies' Q1 results are likely to reflect strength in customer demand. Let's see how WST, DXCM and BAX are placed ahead of their earnings releases.
Healthcare: An Essential Sector (3 Stocks to Buy Ahead of Earnings)
by Andrew Rocco
Healthcare stocks are an excellent place to park your money in the current market environment. Due to it's necessity, the sector tends to due well in any economy.
The Zacks Analyst Blog Highlights Bristol-Myers Squibb, Medtronic, Altria Group, Target and FedEx
by Zacks Equity Research
Bristol-Myers Squibb, Medtronic, Altria Group, Target and FedEx are included in this Analyst Blog.
Medtronic (MDT) Flat As Market Sinks: What You Should Know
by Zacks Equity Research
Medtronic (MDT) closed at $89.69 in the latest trading session, marking no change from the prior day.
Q1 Earnings Scorecard and Fresh Analyst Reports for Bristol-Myers, Medtronic & Altria Group
by Sheraz Mian
Q1 Earnings Season Scorecard is included in today's Research Daily in addition to new research reports on Bristol-Myers (BMY), Medtronic(MDT) and Altria Group (MO).
Medtronic (MDT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Medtronic (MDT) closed at $81.65, marking a -0.57% move from the previous day.
Medtronic (MDT) Stock Moves -0.23%: What You Should Know
by Zacks Equity Research
In the latest trading session, Medtronic (MDT) closed at $80.81, marking a -0.23% move from the previous day.
The Zacks Analyst Blog Highlights The Procter & Gamble, PepsiCo, Bank of America, Medtronic and Blackstone
by Zacks Equity Research
The Procter & Gamble, PepsiCo, Bank of America, Medtronic and Blackstone are part of the Zacks Top Analyst Blog.
Medtronic (MDT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Medtronic (MDT) closed the most recent trading day at $80.30, moving +0.04% from the previous trading session.
Top Research Reports for Procter & Gamble, PepsiCo & Bank of America
by Mark Vickery
Today's Research Daily features new research reports on 15 major stocks, including The Procter & Gamble Company (PG), PepsiCo, Inc. (PEP) and Bank of America Corporation (BAC).
Medtronic (MDT) Launches New Venture to Treat Kidney Failure
by Zacks Equity Research
Medtronic's (MDT) new venture is dedicated to reshaping kidney health and driving patient-centered technology solutions.